Details

Autor(en) / Beteiligte

• Scott, Laura A.
• Berni, Thomas R.
• Berni, Ellen R.
• De Vries, Jane
• Currie, Craig J.

Titel

Evaluation of the healthcare resource use and the related financial costs of managing peanut allergy in the United Kingdom

Ist Teil von

• Expert review of clinical immunology, 2019-08, Vol.15 (8), p.889-896

Ort / Verlag

Taylor & Francis

Erscheinungsjahr

2019

Beschreibungen/Notizen

• Aims: We aimed to estimate the resource use and associated costs for patients with peanut allergy (PA) compared to matched controls. Methods: This was a retrospective cohort study using data from the UK Clinical Practice Research Datalink and Hospital Episode Statistics. PA patients were matched to two control cohorts: the first (simple-matched) were matched 1:1 on year of birth, general practice, gender and registration year. The second (atopy-matched) were matched on the same characteristics plus presence/absence of an atopic condition. Prescriptions and primary and secondary care contacts were compared between cases and controls. Results: 15,483 peanut-allergic patients were identified: 13,609 (87.9%) were simple-matched and 9,320 (60.2%) atopy-matched. The total per person annual incremental health-care costs associated with PA were £253 (atopy-matched) and £333 (simple-matched). For those with PA and a prior anaphylaxis incremental costs were £662, for those prescribed an epinephrine autoinjector incremental costs were £392. Extrapolated to the U.K. population, total excess costs of PA were between £33 and 44 million in 2015. Conclusions: Patients with PA had increased health-care contacts and consequently increased associated costs compared to controls. Observation bias should be considered in interpretation, but this study suggests that PA presents significant burden to health-care systems.